FDA Accepts BANZEL(R) (Rufinamide) Oral Suspension NDA For Review

Links shared publicly online about this topic.

1,006
total visits

FDA Accepts BANZEL(R) (Rufinamide) Oral Suspension NDA For Review

Eisai Inc. (Headquarters: Woodcliff Lake, NJ; President and CEO: Lonnel Coats), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) announced that the U.S.

View full resource at medicalnewstoday.com

Tags: FDA, Eisai

Most Recently Shared on July 21, 2010 at 12:14 pm By:

MNT Drug Approvals

FDA Accepts BANZEL(R) (Rufinamide) Oral Suspension NDA For Review http://mnt.to/3GmX #regulatory

2 years ago...

Retweet

Favorite

Also Shared By:

MNT Epilepsy News

Eisai's NDA for BANZEL Oral Suspension accepted for FDA review

news-medical.net — “Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's NDA for BANZEL® (rufinamide) Oral Suspension (40 mg/mL).” View full resource at news-medical.net